Literature DB >> 6567645

Isolation and characterization of a 33,000-dalton fragment of complement Factor B with catalytic and C3b binding activity.

J D Lambris, H J Müller-Eberhard.   

Abstract

Factor B is the zymogen of the catalytic site bearing subunit Bb of the C3/C5 convertase of the alternative pathway of complement. In this study, the location of the C3b binding site and the catalytic site within the Bb subunit were investigated. When human Factor B was treated with porcine elastase, fragments with respective molecular weights of 36,000, 35,000, 33,000, 31,000, and 25,000 were generated. Binding studies showed that only the 33,000-dalton fragment was capable of binding to C3b. The 33,000-dalton fragment was purified using fast protein liquid chromatography and found to be part of the Bb fragment upon testing with monoclonal antibody 15-6-19-1. Amino-terminal amino acid sequence analysis of the 33,000-dalton fragment placed it in the C-terminal half of Bb. The fragment expressed esterolytic activity as evidenced by cleavage of the synthetic substrate N alpha-acetyl-glycyl-L-lysine methyl ester and restored alternative pathway activity in Factor B-depleted serum. Its hemolytic activity was approximately 60-fold lower than that of Factor B. Comparative binding studies in the presence of metal ions using zymosan-C3b showed that the 33,000-dalton fragment bound to C3b with higher affinity than Factor B. Addition of the fragment to human serum inhibited alternative pathway activation by rabbit erythrocytes due to its high affinity for C3b and its low hemolytic activity compared to Factor B. These results show that the C-terminal 33,000-dalton portion of Bb contains not only the enzymatic site of Bb but also a C3b binding site which confers hemolytic activity upon the fragment. The observation that the fragment inhibited alternative pathway activation suggests that a synthetic peptide may be constructed that exhibits negative regulator activity in the alternative pathway.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6567645

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  New structural motifs on the chymotrypsin fold and their potential roles in complement factor B.

Authors:  H Jing; Y Xu; M Carson; D Moore; K J Macon; J E Volanakis; S V Narayana
Journal:  EMBO J       Date:  2000-01-17       Impact factor: 11.598

Review 2.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

3.  Murine monoclonal anti-Ba antibody that enhances haemolytic activity of factor B.

Authors:  E Tanaka; K Hong; T Kinoshita; Y Takata; H Kozono; J Takeda; A Yoden; K Inoue
Journal:  Immunology       Date:  1991-08       Impact factor: 7.397

4.  Production and functional activity of a recombinant von Willebrand factor-A domain from human complement factor B.

Authors:  S C Williams; J Hinshelwood; S J Perkins; R B Sim
Journal:  Biochem J       Date:  1999-09-15       Impact factor: 3.857

5.  The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).

Authors:  Fredrik Bexborn; Per Ola Andersson; Hui Chen; Bo Nilsson; Kristina N Ekdahl
Journal:  Mol Immunol       Date:  2007-12-21       Impact factor: 4.407

6.  The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb.

Authors:  Vengadesan Krishnan; Karthe Ponnuraj; Yuanyuan Xu; Kevin Macon; John E Volanakis; Sthanam V L Narayana
Journal:  Structure       Date:  2009-04-15       Impact factor: 5.006

7.  The Bb fragment of complement factor B acts as a B cell growth factor.

Authors:  M G Peters; J L Ambrus; A S Fauci; E J Brown
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.